Abstract | OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of ticlopidine. Comparisons with other antiplatelet agents are presented, with an emphasis on efficacy, and a recommendation is provided regarding ticlopidine's place in therapy. DATA SOURCES: A MEDLINE literature retrieval of English-language journal articles from 1987 to January 1993 and references identified from bibliographies of review articles and clinical trials. STUDY SELECTION: DATA EXTRACTION: Clinical trials were reviewed in terms of study design, efficacy results, and toxicity. DATA SYNTHESIS: CONCLUSIONS:
Ticlopidine is a reasonable alternative for use in preventing stroke among patients unable to take aspirin or those who do not benefit from aspirin therapy. Its use as first-line therapy is limited by its high cost and the occurrence of hematologic adverse effects.
|
Authors | P Flores-Runk, R H Raasch |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 27
Issue 9
Pg. 1090-8
(Sep 1993)
ISSN: 1060-0280 [Print] United States |
PMID | 8219445
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Ticlopidine
|
Topics |
- Cardiovascular Diseases
(prevention & control)
- Cerebrovascular Disorders
(prevention & control)
- Clinical Trials as Topic
- Drug Interactions
- Humans
- Ischemic Attack, Transient
(prevention & control)
- Platelet Aggregation Inhibitors
(therapeutic use)
- Ticlopidine
(pharmacokinetics, pharmacology, therapeutic use)
|